Tenpoint Therapeutics
Developing a novel therapy to treat presbyopia.
Sector
Life SciencesCategory
TherapeuticsLocations
London, UKPhiladelphia, US
Initial Investment
2020
Developing a novel therapy to treat presbyopia.
Tenpoint Therapeutics™ is pioneering a new treatment for presbyopia, BRIMOCHOL™ PF, with a PDUFA date from US FDA of January 28, 2026. The company also has a R&D pipeline of novel therapies for other unmet needs in ophthalmology.